ArticleJournal of cellular and molecular medicine2025
TGFBI Inhibits the Pyroptosis of Macrophages to Ameliorate Septic Shock.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation.Molecular oncology · 2026Article
- RUNX3: a regulator of macrophage apoptosis with positive prognostic impact in sepsis.Genes & genomics · 2026Article
- TGFBI in tumors and the tumor immune microenvironment: functional roles, mechanisms, and therapeutic targeting.Frontiers in immunology · 2026Review
- TGFBI Inhibits the Pyroptosis of Macrophages to Ameliorate Septic Shock.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Septic shock is one of the leading causes of morbidity and mortality in hospital patients. The present study aimed to investigate the potential of transforming growth factor β induced (TGFBI) in macrophage functions and progression of septic shock. Mice were treated with caecal ligation and puncture (CLP) to establish a septic shock model in vivo. Histopathologic analysis was performed using haematoxylin and eosin (HE) staining. Gene expression was detected using reverse transcription-quantitative PCR and Western blot. Cytokine release was detected using an enzyme-linked immunosorbent assay. The enrichment of TGFBI was detected using chromatin immunoprecipitation assay. Cellular functions were detected using Cell Counting Kit-8, lactate dehydrogenase, flow cytometry, PI staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling staining assays. TGFBI was downregulated in septic shock patients and models. TGFBI overexpression suppressed the pyroptosis of macrophages by inhibiting the non-canonical inflammasome, promoting the bacterial killing ability of macrophages. Wedelolactone-mediated inhibition of pyroptosis alleviated sepsis-induced multiple organ failure. Moreover, TGFBI inhibited M1 macrophage polarisation. Suppressor of variegation 3-9 homologue 2 (SUV39H2)-mediated histone methylation of TGFBI, resulting in the downregulation of TGFBI. Signal transducer and activator of transcription 1 (Stat1) was identified as a new co-activator of SUV39H2 to inhibit the transcription of TGFBI. However, inhibition of SUV39H2 and Stat1 upregulated TGFBI. Furthermore, Stat1 deficiency inhibited the pyroptosis of macrophages and alleviated sepsis-induced multiple organ failure. In summary, our findings establish an immune checkpoint, whereby TGFBI, via inhibiting macrophage pyroptosis and M1 polarisation, suppresses the progression of septic shock.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.